<DOC>
	<DOCNO>NCT00317577</DOCNO>
	<brief_summary>Low-pressure ( normal tension ) glaucoma type open-angle glaucoma result damage optic nerve abnormality visual field . Eye ( intraocular ) pressure type glaucoma higher usually consider normal ( less 21 mmHg ) eye . The present treatment low-pressure glaucoma also direct lower “ normal ” eye pressure . Both medication study , brimonidine timolol , low eye pressure . Laboratory research past decade indicate potential treat glaucoma lower eye pressure , treatment aim damage occur optic nerve . One group drug , selective alpha2-adrenergic agonist , show laboratory animal protect effect nerve damage follow local stroke . Brimonidine , one medication current study , selective alpha2-adrenergic agonist protects damage optic nerve animal model glaucoma.. The hypothesis present study brimonidine eye drop provide protection damage optic nerve independent lower eye pressure patient low-pressure glaucoma . This determine ( 1 ) measure eye pressure , ( 2 ) perform visual field examination , ( 3 ) examination optic nerve .</brief_summary>
	<brief_title>Study Medical Treatment Low-Pressure ( Normal Tension ) Glaucoma</brief_title>
	<detailed_description>The term glaucoma describe specific pattern optic nerve head visual field damage cause number different disease eye , ( ) associate elevate eye pressure . Glaucoma currently consider progressive neurodegenerative disorder . Low-pressure glaucoma ( LPG ) type open-angle glaucoma ( OAG ) progressive visual field optic nerve damage despite untreated eye pressure statistically normal ( mean 15.9 , SD 2.9 mmHg ) range , usually less 21 mmHg . Therefore , condition , pressure-independent mechanism ( e.g. , vascular structural defect optic nerve ) may main , sole , cause optic neuropathy . LPG represent 6.7 % 68.3 % OAGs . Current glaucoma treatment direct lower eye pressure use medical therapy ( eye drop ) , laser treatment , and/or surgery , level stop progressive optic nerve damage . The efficacy lower eye pressure LPG report . Both protocol medical treatment , brimonidine timolol , show similar efficacy low eye pressure . Laboratory research past decade indicate potential manage glaucoma lower eye pressure , treatment modality aim damage occur optic nerve . Possible therapy may include agent effective neuronal protectants increase prolong survival rate injure retinal ganglion cell . Treatments could also direct rescue nerve fiber secondary degeneration , stimulant expand dendritic field , promote nerve regeneration neural transplantation . Selective α2-adrenergic agonist show neuroprotective effect animal model focal cerebral ischemia . Brimonidine report protect optic nerve retinal ganglion cell secondary degeneration follow partial crush lesion adult rat optic nerve . One molecular mechanism neuroprotection may relate up-regulation neuronal survival factor . In rat , systemic α2-adrenergic agonist induce basic fibroblast growth factor mRNA retina . Treatment α2-agonists constant light exposure reduce retinal photoreceptor degeneration albino rat . Animal study demonstrate topical administration brimonidine result pharmacologic concentration drug vitreous ( 100-170 nM ) . Therefore , ocular dose brimonidine provide route drug delivery retina amount sufficient bind activate α2-adrenoceptor provide neuroprotective effect . The study hypothesis evaluate ability topical treatment 0.2 % brimonidine , highly selective α2-adrenergic agonist , impart neuroprotection damage optic nerve patient LPG . Comparison make 0.5 % timolol , nonselective β-adrenergic antagonist , without report neuroprotective property . Patients randomly assign twice daily double-masked treatment one drug . Neuroprotection assess evaluation automate static visual field perform 4 month interval 4 year treatment .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Age : 30 year old . Lowpressure glaucoma least one eye : untreated IOP &lt; 21 mmHg , glaucomatous field loss Humphrey 242 perimetry , optic disc cup . Best correct visual acuity least 20/40 least one eye . At least two visual field within 6 month prior enrollment . Phakic pseudophakic ( cataract surgery &gt; one year enrollment ) eye . Either eye patient exclusion : Past history confirm treat untreated applanation IOP &gt; 21 mmHg . Untreated IOP &gt; 21 mmHg diurnal curve Study Day 0 . Untreated IOP &gt; 4 mmHg difference two eye . Extensive field damage : MD &gt; 15 dB threat fixation hemi field . Evidence exfoliation pigment dispersion . History angleclosure occludable gonioscopic anterior chamber angle . Prior filtration surgery . Prior laser iridotomy . Laser trabeculoplasty &lt; 6 month prior enrollment IOP &gt; 21 mmHg . History chronic inflammatory eye disease ( e.g. , scleritis , uveitis ) . History sign intraocular trauma . Severe potentially progressive retinal disease . Any abnormality prevent reliable applanation tonometry . History hypersensitivity study medication component . Current use ophthalmic , dermatologic systemic steroid preparation . Therapy another investigational agent within past 30 day . Single eye exclusion : Cataract surgery within past year . Aphakia . Only sight eye . Concomitant condition : Resting pulse &lt; 50 beat per minute . Unstable uncontrolled cardiovascular , renal , pulmonary disease . Recent heart attack stroke . Women contemplate pregnancy , pregnant nursing mother .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Low-pressure glaucoma</keyword>
	<keyword>Normal tension glaucoma</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Brimonidine</keyword>
	<keyword>Visual field progression</keyword>
</DOC>